This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Lipids and Lipid Disorders  • Diabetes Mellitus  • Alert me on articles by topic

Rebecca Voelker

JAMA. 2004;291:2419-2420.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Aggressive new guidelines from the American College of Physicians (ACP) that recommend widespread use of cholesterol-lowering statins to prevent cardiovascular disease in patients with type 2 diabetes mellitus signal a shift from current guidelines that base treatment on target cholesterol levels.

The guidelines, published April 20 in the Annals of Internal Medicine, are the final product of a 3-year ACP initiative to address the high prevalence of type 2 diabetes. Previous recommendations focused on tight blood pressure control in patients with type 2 diabetes (Ann Intern Med. 2003;138:587-592).

"There has been an explosion in the prevalence of diabetes" since the initiative began, said Vincenza Snow, MD, senior medical associate in the ACP's scientific policy department. The new guidelines indicate that an estimated 16 million Americans have type 2 diabetes, and 800 000 new cases are diagnosed annually.

CARDIOVASCULAR RISK CRITICAL

Snow said the ACP wants physicians . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed et al.
Eur Heart J 2006;27:2323-2329.
ABSTRACT | FULL TEXT